-
Mashup Score: 4What about glucagon-like peptide-1 receptor agonist for all? Recent data and perspectives - 7 month(s) ago
Patients with Type 2 diabetes (T2D) make up about one-quarter to one-third of acute coronary syndrome (ACS) patients. Among patients presenting with ACS, those
Source: academic.oup.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 1What about glucagon-like peptide-1 receptor agonist for all? Recent data and perspectives - 7 month(s) ago
Patients with Type 2 diabetes (T2D) make up about one-quarter to one-third of acute coronary syndrome (ACS) patients. Among patients presenting with ACS, those
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet-
What about #GLP1RA for all? Recent data and perspectives.https://t.co/4DhpLf14kp A little bit provocative but it may be a way to move forward in the management of high risk patients. #GLP1RA #Cardiotwitter #T2D #ACS #CAD
-
-
Mashup Score: 1New approaches to reduce recurrent PCI: to angioplasty and beyond! - 11 month(s) ago
Management of coronary artery disease (CAD) patients remains highly challenging, as underlined by the elevated residual risk of ischemic events,1 despite impres
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
New approaches to reduce recurrent PCI: to angioplasty and beyond! | European Heart Journal Open. #PCI #OMT #HolisticApproach #LLT #SAPT #GLP1RA clean copy https://t.co/MA4UbzoiK7
-
-
Mashup Score: 2Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes - PubMed - 11 month(s) ago
Our findings suggest the effect of injectable semaglutide on atherosclerosis as a key CV protective mechanism. Considering the favorable effects on atherogenic lipoproteins and hepatic steatosis indices, our results support the pleiotropic effect of semaglutide beyond glycemic control.
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
#GLP1RA #ASCVD https://t.co/KDj3OqBMDp
-
-
Mashup Score: 17New approaches to reduce recurrent PCI: to angioplasty and beyond! - 11 month(s) ago
Pierre Sabouret, Stéphane Manzo-Silberman, MD, Mirvat Alasnag, Marinos Fysekidis, Martha Gulati, MD, MS, Giuseppe Galati, Luigi Spadafora, Maciej Banach, Giusep
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
RT @SABOURETCardio: #MyEAS #EASCongress2023. How to reduce #MACE with new approaches #LLT #PCSK9i #EPA #GLP1RA https://t.co/L2ArgCKkyb
-
-
Mashup Score: 0Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes - 11 month(s) ago
OBJECTIVE. To evaluate the effects of tirzepatide on body composition, appetite, and energy intake to address the potential mechanisms involved in body weight l
Source: American Diabetes AssociationCategories: Cardiologists, Latest HeadlinesTweet-
#Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in #T2D : the new challenger of #GLP1RA. More potent, ongoing data about efficacy on #MACE and #safety https://t.co/4yAnKzcdgz
-
-
Mashup Score: 14New approaches to reduce recurrent PCI: to angioplasty and beyond! - 12 month(s) ago
Pierre Sabouret, Stéphane Manzo-Silberman, MD, Mirvat Alasnag, Marinos Fysekidis, Martha Gulati, MD, MS, Giuseppe Galati, Luigi Spadafora, Maciej Banach, Giusep
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
RT @SABOURETCardio: #MyEAS #EASCongress2023. How to reduce #MACE with new approaches #LLT #PCSK9i #EPA #GLP1RA https://t.co/L2ArgCKkyb
-
-
Mashup Score: 0New approaches to reduce recurrent PCI: to angioplasty and beyond! - 12 month(s) ago
Pierre Sabouret, Stéphane Manzo-Silberman, MD, Mirvat Alasnag, Marinos Fysekidis, Martha Gulati, MD, MS, Giuseppe Galati, Luigi Spadafora, Maciej Banach, Giusep
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
#MyEAS #EASCongress2023. How to reduce #MACE with new approaches #LLT #PCSK9i #EPA #GLP1RA https://t.co/L2ArgCKkyb
-
-
Mashup Score: 0
This Viewpoint considers the best approaches for treating obesity in youth and argues that better funding is needed for new dietary treatments and reimbursement for behavioral interventions.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
GLP1RAs have been transformative for (wealthy) adults w obesity. But we must tackle root causes. At $1400/mo, #GLP1RA tx of 🇺🇸 adolescents & adults w obesity would cost $100 billion & $1 trillion /yr. #Nutrition #FoodPolicy #GreenSpaces #BuiltEnvironment https://t.co/vcfOASruFd
-
-
Mashup Score: 0
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Cardiologists, Latest HeadlinesTweet-
#Tirzepatide weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2. I guess that they will focus first on diabetologists then they will observe that it will be prescribed by …cardiologists as #GLP1RA🤔. Errare humanum est… https://t.co/NciD1WH2tl
-
RT @SABOURETCardio: What about #GLP1RA for all? Recent data and perspectives.https://t.co/4DhpLf14kp A little bit provocative but it may b…